PT831791E - Entrega de farmacos ao tracto gi inferior - Google Patents

Entrega de farmacos ao tracto gi inferior

Info

Publication number
PT831791E
PT831791E PT96919237T PT96919237T PT831791E PT 831791 E PT831791 E PT 831791E PT 96919237 T PT96919237 T PT 96919237T PT 96919237 T PT96919237 T PT 96919237T PT 831791 E PT831791 E PT 831791E
Authority
PT
Portugal
Prior art keywords
weight
drug
composition
tract
colon
Prior art date
Application number
PT96919237T
Other languages
English (en)
Inventor
David R Friend
David Wong
Original Assignee
Watson Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,974 external-priority patent/US5656294A/en
Application filed by Watson Lab Inc filed Critical Watson Lab Inc
Publication of PT831791E publication Critical patent/PT831791E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT96919237T 1995-06-07 1996-06-07 Entrega de farmacos ao tracto gi inferior PT831791E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/486,974 US5656294A (en) 1995-06-07 1995-06-07 Colonic delivery of drugs
US08/602,611 US5811388A (en) 1995-06-07 1996-02-16 Delivery of drugs to the lower GI tract

Publications (1)

Publication Number Publication Date
PT831791E true PT831791E (pt) 2005-02-28

Family

ID=27048854

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96919237T PT831791E (pt) 1995-06-07 1996-06-07 Entrega de farmacos ao tracto gi inferior

Country Status (11)

Country Link
US (1) US5811388A (pt)
EP (1) EP0831791B1 (pt)
JP (1) JPH11507357A (pt)
AT (1) ATE280572T1 (pt)
AU (1) AU6163096A (pt)
CA (1) CA2224170A1 (pt)
DE (1) DE69633721T2 (pt)
DK (1) DK0831791T3 (pt)
ES (1) ES2231815T3 (pt)
PT (1) PT831791E (pt)
WO (1) WO1996040078A1 (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US6162464A (en) * 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
DK1017404T3 (da) * 1997-09-26 2004-11-01 Celltech Pharma Europ Ltd Farmaceutisk sammensætning til behandling af inflammatorisk tarmsygdom
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6251863B1 (en) 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
DE60005819T2 (de) * 1999-06-14 2004-05-06 Cosmo S.P.A. Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
EA008224B1 (ru) * 2001-03-13 2007-04-27 Пенвест Фармасьютикалз Ко. Хронотерапевтические дозированные формы
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
ES2296898T3 (es) * 2001-09-14 2008-05-01 Scolr, Inc. Forma de dosificacion oral de liberacion prolongada modulada por aminoacidos.
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US7887838B2 (en) 2002-01-18 2011-02-15 Banner Pharmacaps, Inc. Non-gelatin film and method and apparatus for producing same
US6949256B2 (en) * 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
ES2339003T3 (es) * 2002-08-29 2010-05-14 Activbiotics Pharma Llc Rifalazil para tratar infecciones por clostridium difficile.
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
PT1572217E (pt) * 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
US20040142968A1 (en) * 2003-01-17 2004-07-22 Donald Price Method and kit for treating lower bowel pain
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
US20050019294A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible alginate films and soft capsules made therefrom
US7816341B2 (en) * 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
US20050019295A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
US20050048185A1 (en) * 2003-04-14 2005-03-03 Fmc Corporation Delivery systems of homogeneous, thermoreversible low viscosity polymannan gum films
US20050013847A1 (en) * 2003-04-14 2005-01-20 Fmc Corporation Delivery systems of homogeneous, thermoreversible alginate films
US20050008677A1 (en) * 2003-04-14 2005-01-13 Fmc Corporation Delivery system of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
JP2007526209A (ja) * 2003-04-14 2007-09-13 エフ　エム　シー　コーポレーション 均一かつ熱可逆性低粘度ポリマンナンフィルムの伝達システム
CN102525993B (zh) 2003-04-24 2017-04-12 佳高泰克有限公司 具有限定内核几何形状的缓释片剂
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
CA2538202C (en) * 2003-09-15 2013-01-15 Altana Pharma Ag Use of ciclesonide for the treatment of inflammatory bowel diseases
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
CA2579732C (en) * 2004-09-10 2014-08-12 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
AU2011232809B2 (en) * 2004-09-10 2014-03-20 Jagotec Ag Tablets with site and time-controlled gastrointestinal release of active ingredient
DE102004043863A1 (de) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2012012147A2 (en) 2010-06-30 2012-01-26 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
US10435428B2 (en) 2015-11-24 2019-10-08 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
EP3413875B1 (en) 2016-02-09 2020-01-29 Albireo AB Cholestyramine pellets and methods for preparation thereof
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
WO2018165250A1 (en) 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
EP3609903A1 (en) 2017-05-23 2020-02-19 Theravance Biopharma R&D IP, LLC Thiocarbamate prodrugs of tofacitinib
JP2020520955A (ja) 2017-05-23 2020-07-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ヤヌスキナーゼ阻害剤のグルクロニドプロドラッグ
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
WO2019129360A1 (en) * 2017-12-29 2019-07-04 Laxxon Medical Ag Drug delivery system
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022254456A1 (en) * 2021-06-01 2022-12-08 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN117503717A (zh) * 2023-10-07 2024-02-06 山西农业大学 一种黄芪抗炎口含片及其制备方法
US12599544B2 (en) 2024-05-09 2026-04-14 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
DE2130545A1 (de) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmazeutischer Formkoerper
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4894233A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for decongestants
EP0222883A1 (en) * 1985-05-15 1987-05-27 Riker Laboratories, Inc. Sustained release theophylline compositions and processes
SE8601563D0 (sv) * 1986-04-08 1986-04-08 Carbomatrix Ab Matrismaterial, forfarande for framstellning derav och anvendning derav
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5466469A (en) * 1988-06-28 1995-11-14 Cibus Pharmaceutical, Inc. Granular drug delivery system
CA1334379C (en) * 1987-11-24 1995-02-14 James William Mcginity Method for preparing a solid sustained release form of a functionally active composition
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5445826A (en) * 1988-06-28 1995-08-29 Cibus Pharmaceutical, Inc. Delivery system containing a gel-forming dietary fiber and a drug
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
JP2683391B2 (ja) * 1988-11-30 1997-11-26 日清製粉株式会社 小麦ふすまからのヘミセルロースを基材とする徐放性組成物
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
HU210497B (en) * 1990-05-04 1995-04-28 Perio Prod Ltd Process for production of modified pectin
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
FR2667242B1 (fr) * 1990-09-28 1994-11-25 Rhone Poulenc Sante Nouvelles formes orales a liberation prolongee avec un temps de latence au niveau stomacal amoindri.
DE4131292A1 (de) * 1990-10-18 1992-04-23 Asta Pharma Ag Galactomannanderivate zur umhuellung oder einbettung von arzneimittelwirkstoffen
DE9015551U1 (de) * 1990-11-14 1992-03-12 Röhm GmbH, 6100 Darmstadt Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccarid
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
EP0676967A4 (en) * 1992-12-30 1996-10-02 Fmc Corp RELEASED, EXTENDED, EASY TO PRODUCE EXCIPIENT, BASED ON KONJAC GLUCOMANNANE.
EP0804169A4 (en) * 1994-12-01 1998-08-19 Cibus Pharmaceutical Inc NSAID ADMINISTRATION USING A POWDERED HYDROCOLLOID GUM MACHINABLE FROM HIGHER PLANTS
CN1172429A (zh) * 1994-12-01 1998-02-04 希博斯药物公司 使用从高等植物中可得到的粉末状水解胶体树胶的持续释放药物运送体系
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs

Also Published As

Publication number Publication date
CA2224170A1 (en) 1996-12-19
DK0831791T3 (da) 2005-01-31
DE69633721D1 (de) 2004-12-02
EP0831791B1 (en) 2004-10-27
EP0831791A1 (en) 1998-04-01
ES2231815T3 (es) 2005-05-16
JPH11507357A (ja) 1999-06-29
US5811388A (en) 1998-09-22
ATE280572T1 (de) 2004-11-15
DE69633721T2 (de) 2005-12-22
AU6163096A (en) 1996-12-30
WO1996040078A1 (en) 1996-12-19
EP0831791A4 (en) 1998-08-26

Similar Documents

Publication Publication Date Title
EP0831791A4 (en) ADMINISTRATION OF MEDICINAL PRODUCTS IN THE LOWER DIGESTIVE TRACT
DE69630460T2 (de) Flurbiprofenhaltige arzneimittel
JP2005515966A5 (pt)
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
DZ1884A1 (fr) Formulations orales liquides d'alendronate.
ATE145819T1 (de) Inhalierbare arzneimittel
MY125662A (en) Pharmaceutical formulations containing darifenacin
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
NO895167L (no) Fremgangsmaate for behandling av tannrotsykdom ved vedvarende avgivelse av et farmasoeytisk middel til crevikularlommen, stoffblanding for dette og apparat for administrering derav.
DE69532678D1 (de) Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende Arzneimittel
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
DE69101314D1 (de) Dosierungsform zur verabreichung eines arzneimittels an die därme.
KR950700056A (ko) 분무-냉각된 나부메톤(Spray-chilled nabumetone)
Berry et al. Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis.
JP2002540148A5 (pt)
CA1306950C (en) Buccal administration of estrogens
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
JPH08295637A (ja) 口腔部局所投与剤
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
NO972486L (no) Vedvarende frigjöring av legemiddel ved anvendelse av en pulverisert hydrokolloid-gummi som kan oppnås fra höyere planter
JP2000500159A (ja) メラトニンと組み合わせた鎮痛剤
CN1053810C (zh) 复方解热止痛抗炎胶囊
SU449724A1 (ru) Отхаркивающее средство "мукалтин'
JPH0967256A (ja) 感冒薬
Miller et al. Section 3 Clinical studies of ibuprofen